NCT05376319终止2 期
A Randomized, Double-Blind, Active Comparator-Controlled Study to Evaluate the Effect of Obinutuzumab Versus Rituximab in PR3-Patients With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- Mayo Clinic
- 入组人数
- 6
- 试验地点
- 6
- 主要终点
- Number of Patients to Achieve Both Complete Remission and Seronegativity for ANCA.
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of obinutuzumab for the treatment of proteinase 3 Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis (PR3-AAV).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Fulfillment of the definitions of the Second Chapel Hill Consensus Conference for ANCA-associated vasculitis (either granulomatosis with polyangiitis or microscopic polyangiitis).
- •Positivity for ANCA, directed against proteinase-3 (PR3)
- •Severe newly-diagnosed disease or severe relapsing disease. Severe relapsing disease is defined as at least one major BVAS/WG item or a score ≥ 3 and the investigator deems standard treatment for severe disease is necessary.
- •Minimum BVAS/WG of 3
- •Relapsing patients must have B cells detectable in the peripheral blood.
- •Patients must have completed COVID19 vaccination (including booster if eligible) at least 4 weeks prior to enrollment with a positive spike protein antibody test result. Patients who have recovered from COVID19 prior to screening with a positive spike protein antibody test result but have not been vaccinated are also eligible.
- •Female subjects of childbearing potential who are not sterile must agree to use an acceptable method of contraception for 18 months after the last dose of infusion medication. Male subjects who are not sterile whose female partners are of childbearing potential must agree to use an acceptable method of contraception for 180 days after the last dose of infusion medication.
- •Females of childbearing potential include any female who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (to be considered postmenopausal, the patient must have had amenorrhea for >12 consecutive months).
- •Acceptable methods of contraception include the use of at least two of the following: 1) intrauterine device; 2) hormonal contraceptives for at least 30 days prior to first dose infusion (oral, injectable, implant or ring); 3) barrier contraceptives (condom or diaphragm) with spermicide; or 4) abstinence.
排除标准
- •Diagnosis with eosinophilic granulomatosis with polyangiitis (formerly Churg-Strauss syndrome) as defined by the Chapel Hill Consensus Conference.
- •Positive serum assays for ANCA directed against myeloperoxidase (MPO-ANCA)
- •Non-severe AAV, defined as disease that does not justify treatment with both B cell depletion and a four-month glucocorticoid taper.
- •Any of the co-morbidities:
- •Allergies: a history of severe allergic reactions to human or chimeric monoclonal antibodies or murine protein.
- •Infection (systemic): an active systemic infection at screening visit
- •Infection (deep space): have been diagnosed as having a deep-space infection, such as osteomyelitis, septic arthritis, or pneumonia complicated by empyema or lung abscesses, within 6 months prior to the screening visit
- •Infection (blood borne): active hepatitis B or active hepatitis C or a documented history of HIV, hepatitis B, or hepatitis C
- •Infection (history): History of recurrent significant infection or history of recurrent bacterial infections
- •Liver disease: acute or chronic liver disease that is deemed sufficiently severe to impair their ability to participate in the trial.
- •Renal disease: a history of documented anti-glomerular basement membrane disease (anti-GBM disease).
- •Malignancy: Active or history of malignancy in the last 5 years. Individuals with squamous cell or basal cell skin carcinomas and individuals with cervical carcinoma in situ may be enrolled if they have received curative surgical treatment.
- •Active COVID-19 infection.
- •Uncontrolled disease: evidence of glucocorticoid dependent disease (such as asthma, COPD, psoriasis or IBD, etc.) requiring consistently greater than 10 mg of prednisone for disease control which might affect endpoint assessment or,
- •Other uncontrolled diseases, including any uncontrolled psychiatric disorders, drug and alcohol abuse, that could interfere with participation in the trial according to the protocol.
- •Diagnosis of human anti-chimeric antibodies (HACA) formation.
- •Subjects who are premenopausal and are:
- •Pregnant on the basis of a serum pregnancy test,
- •Breastfeeding, or
- •Do not agree to use effective method(s) of contraception
- •Use of prohibited medications: They have used any of the prohibited medication listed in Section 5.9.
- •Plasma exchange: They have been treated with plasma exchange within the 3 months preceding the screening visit.
- •History of intolerance to rituximab or other chimeric monoclonal antibodies (e.g., infliximab).
- •Recent vaccination: They have had a live vaccine fewer than 4 weeks (28 days) before or during randomization (vaccination with live vaccine through the end of study participation is contraindicated).
- •Daily use of non-steroidal anti-inflammatory drugs (NSAIDs)
- •Exclusion criteria related to laboratory parameters:
- •Bone marrow suppression as evidenced by a total white count < 4 x10 /l, hemoglobin < 7 gm/dl or platelet count < 100,000/μl
- •Aspartate aminotransferase or alanine aminotransferase or amylase > 2.5 times the upper limit of normal, unless attributed to vasculitis
研究组 & 干预措施
Intravenous dose of obinutuzumab
Experimental
Subjects who have clinical diagnoses of either granulomatosis with polyangiitis or microscopic polyangiitis will receive two intravenous doses of obinutuzumab
干预措施: Obinutuzumab (Drug)
Intravenous dose of rituximab
Active Comparator
Subjects who have clinical diagnoses of either granulomatosis with polyangiitis or microscopic polyangiitis will receive two intravenous doses of rituximab
干预措施: Rituximab (Drug)
结局指标
主要结局
Number of Patients to Achieve Both Complete Remission and Seronegativity for ANCA.
时间窗: 6 months
Complete remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) of 0 without glucocorticoids beyond the prescribed prednisone taper. Seronegativity for ANCA is defined as a negative test for antibodies directed against serine proteinase 3 (i.e., a negative PR3-ANCA assay).
次要结局
- Number of Patients to Achieve Sustained Complete Remission 6 Months(6 months)
- Number of Patients to Achieve Sustained Complete Remission 18 Months(18 months)
- Number of Patients to Achieve Sustained Complete Remission 12 Months(12 months)
研究者
Ulrich Specks, MD
Principal Investigator
Mayo Clinic
研究点 (6)
Loading locations...
相似试验
进行中（未招募）
3 期
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2003 Class III or IV Lupus NephritisLupus NephritisNCT04221477Hoffmann-La Roche271
招募中
2 期
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaMantle Cell LymphomaNCT06504199Institute of Hematology & Blood Diseases Hospital, China39
已完成
1 期
A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)LymphomaNCT02729896Hoffmann-La Roche36
撤回
1 期
Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.Chronic Lymphocytic LeukemiaNCT02611908Michael Choi
招募中
2 期
Obinutuzumab in Treatment of Fibrillary GlomerulonephritisFibrillary GlomerulonephritisNCT06295770Mayo Clinic20